Previous close | 40.40 |
Open | 39.10 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 36.38 - 39.10 |
52-week range | 31.02 - 50.10 |
Volume | |
Avg. volume | 2,981 |
Market cap | N/A |
Beta (5Y monthly) | 0.63 |
PE ratio (TTM) | 0.17 |
EPS (TTM) | 2.09 |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Although the revenue and EPS for Baxter (BAX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Baxter (BAX) reports better-than-expected first-quarter earnings and sales. BAX's quarterly results reflect solid demand for a range of its medically essential products.
Robust Operational Performance Drives Growth Amidst Strategic Transformations